Free Trial

ALT5 Sigma (ALTS) Competitors

ALT5 Sigma logo
$7.21 +0.25 (+3.59%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$7.32 +0.12 (+1.60%)
As of 08/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALTS vs. KURA, SAGE, ORKA, SLDB, SEPN, OPT, PGEN, RZLT, RAPP, and TERN

Should you be buying ALT5 Sigma stock or one of its competitors? The main competitors of ALT5 Sigma include Kura Oncology (KURA), Sage Therapeutics (SAGE), Oruka Therapeutics (ORKA), Solid Biosciences (SLDB), Septerna (SEPN), Opthea (OPT), Precigen (PGEN), Rezolute (RZLT), Rapport Therapeutics (RAPP), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry.

ALT5 Sigma vs. Its Competitors

Kura Oncology (NASDAQ:KURA) and ALT5 Sigma (NASDAQ:ALTS) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

In the previous week, Kura Oncology and Kura Oncology both had 17 articles in the media. ALT5 Sigma's average media sentiment score of 0.76 beat Kura Oncology's score of -0.10 indicating that ALT5 Sigma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kura Oncology
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral
ALT5 Sigma
6 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kura Oncology has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

ALT5 Sigma has lower revenue, but higher earnings than Kura Oncology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kura Oncology$53.88M10.63-$173.98M-$2.26-2.92
ALT5 Sigma$12.53M12.43-$6.24MN/AN/A

Kura Oncology has a net margin of 0.00% compared to ALT5 Sigma's net margin of -74.89%. Kura Oncology's return on equity of -52.32% beat ALT5 Sigma's return on equity.

Company Net Margins Return on Equity Return on Assets
Kura OncologyN/A -52.32% -29.59%
ALT5 Sigma -74.89%-179.27%-16.28%

Kura Oncology currently has a consensus price target of $24.10, indicating a potential upside of 265.15%. Given Kura Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe Kura Oncology is more favorable than ALT5 Sigma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology
0 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.86
ALT5 Sigma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

6.3% of ALT5 Sigma shares are held by institutional investors. 6.4% of Kura Oncology shares are held by company insiders. Comparatively, 4.9% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Kura Oncology beats ALT5 Sigma on 8 of the 14 factors compared between the two stocks.

Get ALT5 Sigma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALTS vs. The Competition

MetricALT5 SigmaFIN IndustryFinance SectorNASDAQ Exchange
Market Cap$150.40M$7.84B$12.42B$9.84B
Dividend YieldN/A4.76%5.54%4.07%
P/E RatioN/A19.3219.6925.74
Price / Sales12.436.8325.79115.83
Price / CashN/A21.5721.7659.48
Price / Book13.114.372.296.15
Net Income-$6.24M$311.03M$1.00B$265.06M
7 Day Performance-19.62%2.72%1.75%2.60%
1 Month Performance0.56%9.04%2.42%2.83%
1 Year Performance298.34%32.98%542.40%25.58%

ALT5 Sigma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALTS
ALT5 Sigma
0.6327 of 5 stars
$7.21
+3.6%
N/A+321.6%$150.40M$12.53M0.00170Trending News
Options Volume
Gap Up
High Trading Volume
KURA
Kura Oncology
4.0102 of 5 stars
$6.36
+0.6%
$24.50
+285.2%
-65.3%$547.15M$53.88M-3.03130
SAGE
Sage Therapeutics
3.9248 of 5 stars
$8.68
flat
$7.85
-9.6%
N/A$543.54M$41.24M-1.78690
ORKA
Oruka Therapeutics
2.964 of 5 stars
$15.50
+8.4%
$40.38
+160.5%
N/A$535.40MN/A-3.44N/ANews Coverage
Earnings Report
Analyst Forecast
Analyst Revision
SLDB
Solid Biosciences
3.5131 of 5 stars
$6.70
-1.8%
$15.10
+125.4%
-26.1%$528.66M$8.09M-2.24100News Coverage
Earnings Report
Analyst Forecast
Analyst Revision
SEPN
Septerna
1.7447 of 5 stars
$11.65
-1.6%
$26.75
+129.6%
N/A$527.57M$1.08M0.00N/ANews Coverage
Earnings Report
Upcoming Earnings
Analyst Revision
OPT
Opthea
0.4012 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
+47.6%$524.84M$120K0.008News Coverage
Gap Up
High Trading Volume
PGEN
Precigen
4.0486 of 5 stars
$1.93
+9.7%
$6.00
+210.9%
+65.2%$519.52M$3.92M-3.45190News Coverage
Earnings Report
Analyst Forecast
Analyst Revision
RZLT
Rezolute
3.1909 of 5 stars
$5.86
-0.7%
$12.20
+108.2%
+48.5%$513.28MN/A-5.1040Positive News
RAPP
Rapport Therapeutics
1.7603 of 5 stars
$14.43
+2.8%
$28.00
+94.0%
-26.8%$512.43MN/A-4.18N/AEarnings Report
Analyst Revision
TERN
Terns Pharmaceuticals
4.0271 of 5 stars
$6.08
+5.7%
$15.63
+157.0%
+4.3%$502.19MN/A-5.5840

Related Companies and Tools


This page (NASDAQ:ALTS) was last updated on 8/15/2025 by MarketBeat.com Staff
From Our Partners